Dr. Girindra Raval sat down for an interview with CURE to discuss what patients with EGFR-mutated lung cancer should know about their treatment options, highlighting the latest advancements in ...
DEAR DR. ROACH: I am a 73-year-old female. A recent blood test returned an eGFR (estimated glomerular filtration rate) of 59. My physician’s nurse told me that the test was normal. When I asked her ...
In the past several years, our understanding of lung cancer has become much more detailed and nuanced. "When I started [practicing medicine about 20 years ago], lung cancer was just small cell lung ...
Johnson & Johnson today announced final overall survival (OS) results from the Asia patients of the Phase 3 MARIPOSA study. Head-to-head comparison data versus osimertinib monotherapy showed ...
Michelle Afkhami, MD, of City of Hope, joins The American Journal of Managed Care® (AJMC®) for a discussion on EGFR exon 20 insertion positive mutations in non-small cell lung cancer. Michelle Afkhami ...
20 years on from the approval of the first intentional kinase inhibitor, the field remains locked in a battle of trial and error. For proof, look no further than EGFR ...
In DUBLIN-3 non-squamous EGFR WT NSCLC patients who progressed after anti-PD-(L)1, Plinabulin + docetaxel showed consistent and clinically meaningful improvements in OS, PFS, and ORR, reinforcing ...
In DUBLIN-3 non-squamous EGFR WT NSCLC patients who progressed after anti-PD-(L)1, Plinabulin + docetaxel showed consistent and clinically ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback